A new medication just approved by the FDA could revolutionize the treatment of postpartum depression. Here's what to know about the new drug:
The medication, zuranolone, to be sold under the brand name Zurzuvae, is the first oral pill to ever be approved by the FDA to treat postpartum depression, a depression that occurs after having a baby.
Symptoms of postpartum depression include withdrawing from loved ones, crying more than usual, feeling worried or overly anxious, feeling anger, doubting your ability to take care of your baby and thinking about harming yourself or your baby, according to the
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
Update: H1-KEY Unveils 1st Concept Photos For “Seoul Dreaming” ComebackUpdate: H1-KEY Unveils 1st Concept Photos For “Seoul Dreaming” Comeback
Les mer »
FDA approves first pill specifically designed to treat postpartum depressionFDA APPROVED: Doctors say postpartum depression is a condition that can start during pregnancy with symptoms such as feelings of sadness, guilt, loss of energy and difficulty sleeping.
Les mer »
Sage Therapeutics stock plunges 48% after FDA decision on postpartum depression drugThe FDA approved the pill Zuranolone, developed by Sage and Biogen, for postpartum depression but declined to approve it for major depressive disorder.
Les mer »
FDA approves first postpartum depression pillThe medication is a first-of-its-kind treatment in the United States for a condition that affects thousands of new mothers every year.
Les mer »
FDA Approves First Pill to Treat Postpartum DepressionThe FDA has approved a breakthrough pill for the treatment of postpartum depression. The pill, which takes effect in as little as three days, could be available for use by November. A recent study showed significant improvements in depressive symptoms for women taking a 50-milligram dose for two weeks.
Les mer »